Joseph Kennedy Net Worth

The estimated Net Worth of Joseph T Kennedy is at least $4.23 Million dollars as of 30 July 2021. Mr. Kennedy owns over 7,220 units of Amarin Corp stock worth over $189,781 and over the last 5 years he sold AMRN stock worth over $1,057,711. In addition, he makes $2,983,330 as Executive Vice President, General Counsel, Secretary, and Strategic Initiatives at Amarin Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Kennedy AMRN stock SEC Form 4 insiders trading

Joseph has made over 24 trades of the Amarin Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 7,220 units of AMRN stock worth $4,260 on 30 July 2021.

The largest trade he's ever made was exercising 128,286 units of Amarin Corp stock on 25 February 2021 worth over $75,689. On average, Joseph trades about 21,787 units every 33 days since 2019. As of 30 July 2021 he still owns at least 321,663 units of Amarin Corp stock.

You can see the complete history of Mr. Kennedy stock trades at the bottom of the page.

Joseph Kennedy biography

Joseph T. Kennedy J.D. serves as Executive Vice President, General Counsel, Secretary, Strategic Initiatives of the Company. He was promoted to Executive Vice President, General Counsel and Strategic Initiatives in July 2015 and no longer serves as the company’s compliance officer for pharmaceutical industry matters as of August 2017. From March 2009 to December 2011, he was Vice President, General Counsel and Secretary of Transcept Pharmaceuticals, Inc., where he played a lead role negotiating the company’s strategic collaboration with Purdue Pharma, helped obtain U.S. Food and Drug Administration (“FDA”) approval for the company’s lead product and had responsibility for all legal and compliance matters affecting the company. Mr. Kennedy represented large pharmaceutical companies, developing life science companies and venture capital firms in private law practice from January 2006 to March 2009. Prior to that, Mr. Kennedy served as Chief Corporate Counsel, then Vice President, Acting Chief Legal Officer with Eyetech Pharmaceuticals, Inc. His work at Eyetech included transitioning the company from private to public, legal matters related to the company’s development and commercialization collaboration with Pfizer Inc., public company and pharmaceutical industry compliance, and the sale of the company to OSI Pharmaceuticals Inc. Previously, Mr. Kennedy served as Vice President and U.S. Counsel, Corporate Business Development, with Élan Corporation, plc where he helped acquire technologies, managed legal issues related to multiple collaborations and participated in the company’s sale of assets that raised over $2.0 billion in a restructuring.

What is the salary of Joseph Kennedy?

As the Executive Vice President, General Counsel, Secretary, and Strategic Initiatives of Amarin Corp, the total compensation of Joseph Kennedy at Amarin Corp is $2,983,330. There are 2 executives at Amarin Corp getting paid more, with John Thero having the highest compensation of $8,929,540.

How old is Joseph Kennedy?

Joseph Kennedy is 52, he's been the Executive Vice President, General Counsel, Secretary, and Strategic Initiatives of Amarin Corp since 2015. There are 13 older and 4 younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.

What's Joseph Kennedy's mailing address?

Joseph's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.

Insiders trading at Amarin Corp

Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum, and David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.

What does Amarin Corp do?

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.

Complete history of Mr. Kennedy stock trades at Amarin Corp

Amarin Corp executives and stock owners

Amarin Corp executives and other stock owners filed with the SEC include:

• John Thero,
  President, Chief Executive Officer, Director
• Stephen Ketchum,
  President - Research and Development, Senior Vice President, Chief Scientific Officer
• Joseph Kennedy,
  Executive Vice President, General Counsel, Secretary, Strategic Initiatives
• Aaron Berg,
  Senior Vice President, Chief Commercial Officer
• Michael Kalb,
  Chief Financial Officer, Senior Vice President, Assistant Secretary
• Joseph Zakrzewski,
  Non-Executive Independent Director
• Dr. Steven B. Ketchum Ph.D.,
  Pres of R&D, Exec. VP and Chief Scientific Officer
• Dr. Steven B. Ketchum,
  Pres of R&D, Sr. VP and Chief Scientific Officer
• Michael W. Kalb,
  CFO, Sr. VP & Assistant Sec.
• Aaron D. Berg,
  Exec. VP & Pres of U.S.
• Elisabeth Schwartz,
  IR Contact Officer
• Jan van Heek,
  Non-Executive Independent Director
• David Stack,
  Non-Executive Independent Director
• Kristine Peterson,
  Non-Executive Independent Director
• Patrick O'Sullivan,
  Non-Executive Independent Director
• Lars Ekman,
  Non-Executive Independent Chairman of the Board
• Alan J. Wills B.A., BA (Zoology), M.B.A., MBA,
  Exec. VP of Corp. Bus. Devel.
• Jason M. Marks J.D.,
  Chief Legal Officer & Corp. Sec.
• Karim Mikhail,
  Pres, CEO & Director
• Donna Pasek,
  Sr. VP of HR
• Rami Daoud,
  Sr. VP of Corp. Devel.
• Alina Kolomeyer,
  Director of Communications
• Daniel S. Dunham,
  Sr. VP & Chief Pharmaceutical Compliance Officer
• Healthcare Partners Ltd. Fo...,
  Director
• Louis Iii Sterling,
  
• Oliver O'connor,
  
• Paul Cohen,
  
• Kostas D Odysseas,
  
• Mark Di Paolo,
  
• Steven B Ketchum,
  Chief Scientific Officer
• Murray Stewart,
  
• Karim Mikhail,
  President and CEO
• Jason M. Marks,
  EVP,Chief Global Legal Officer
• Alfonso G Zulueta,
  
• Erin S. Enright,
  
• Thomas Charles Reilly,
  EVP and CFO
• Geraldine Murphy,
  
• Adam Mark Berger,
  
• Diane E. Sullivan,
  
• Olsen Per Wold,
  Director
• Keith Horn,
  
• Jonathan Provoost,
  EVP, Chief Legal Officer
• Patrice Eadon Bonfiglio,
  
• Patrick Holt,
  President and CEO